Researchers at UC San Diego School of Medicine and Moores Cancer Center are working with GSK on a bench-to-bedside project to treat leukemia and other diseases by eliminating cancer stem cells. The collaboration is part of GSK’s Discovery Partnerships with Academia (DPAc) program, where academic partners become core members of drug-hunting teams. MCC Investigator Catriona Jamieson, MD, PhD, associate professor of medicine and chief of the Division of Regenerative Medicine, will lead UC San Diego’s effort in the new DPAc team.
» UC San Diego Health System Press Release
» San Diego Union Tribune article
February 22, 2015
CIRM's Klein proposes $100B biomed program: Bob Klein describes his vision of how to increase biomedical funding to hasten discovery and commercialization of disease treatments. He spoke Thursday, Feb. 19, at the annual UCSD Moores Cancer Center symposium.
» San Diego Union Tribune article
February 21, 2015
Fighting patient, fighting doctor: : Patient Theresa Blanda speaks about her experience battling cancer with the help of Moores Cancer Center Investigator Dr. Catriona Jamieson, at the 11th annual Industry/Academia Translational Oncology Symposium.
» San Diego Union Tribune article
February 19, 2015
Katherine Connor from the San Diego Daily Transcript reports on the new funding paradigm needed for scientific research: Some of the nation’s top oncology researchers and private companies in the cancer space met at the University of California, San Diego Moores Cancer Center Thursday for the 11th annual Industry/Academic Translational Oncology Symposium.
» San Diego Daily Transcript article
February 13, 2015
The Union-Tribune published an opinion editorial by Moores Cancer Center Director of Industry Relations Ida Deichaite, PhD, entitled "Finding Ways to create cancer-killing swords". The op-ed features the upcoming 11th Annual Moores Cancer Center Industry/Academia Translational Oncology Symposium on February 19, and the ongoing collaborations at MCC.
» Union Tribune Op-ed
January 12, 2015
Trovagene Collaborates with UC San Diego Moores Cancer Center to Demonstrate Clinical Utility of Detecting and Monitoring EGFR Mutations in Lung Cancer Patients. The lead investigator in the study is Assistant Professor of Hematology-Oncology Dr. Hatim Husain.
» Press Release
February 18, 2014
San Diego ABC 10 News reporter Michael Chen interviewed San Diego resident Heather Clark, a patient of Moores Cancer Center, along with Ida Deichaite, Director of Industry Relations & Symposium Organizer, in a video report about the I-SPY Clinical Trial and upcoming Symposium. The I-SPY Clinical Trial is lead by Symposium Keynote Speaker and Principle Investigator Laura Esserman, MD, MBA.
» Full Video and Article
A decade of fostering collaborations, fueling innovation & saving lives
San Diego ABC 10 News reporter Michael Chen interviewed San Diego resident Heather Clark, a patient of Moores Cancer Center, along with Ida Deichaite, Director of Industry Relations & Symposium Organizer, in a video report about the I-SPY Clinical Trial and Symposium. The I-SPY Clinical Trial is lead by Symposium Keynote Speaker and Principle Investigator Laura Esserman, MD, MBA. For the video, see below.
Xconomy’s San Diego Life Sciences Roundup included Bob Klein’s Proposal presented at the Moores Cancer Center Symposium, outlining the $5 billion ballot initiative for funding California Institute for Regenerative Medicine in 2016. » Read Here
Xconomy's San Diego Life Sciences Roundup also included the Moores Cancer Center Symposium and Laura Esserman's acceptance of the Duane Roth Award. » Read Here
The San Diego Daily Transcript published an article about Dr. Esserman's acceptance of the Duane Roth Award and the Symposium. » Read Here
The San Diego Union Tribune wrote an article on the Symposium, namely the iSPY Trial and patient from the trial, San Diego Resident Heather Clark. » Read Here
Symposium Speaker Bob Klein was featured in a San Diego Union Tribune article, outlining the $5 billion ballot initiative for funding California Institute for Regenerative Medicine in 2016, presented at the Moores Cancer Center Symposium. » Read Here
Learn more about our Principal Investigators here at Moores Cancer Center, including their Translational Oncology Research and toolbox of models they use. For all interviews, please see the Principal Investigators page.
Hatim Husain, MD, is an Assistant Professor of Medicine in the Division of Medical Oncology, in the Department of Medicine at UC San Diego. Dr. Husain is a specialist in both lung cancer as well as brain tumors. His work focuses on better understanding the molecular underpinnings of cancer to determine why it forms, how to treat cancer stem-like cells, and how best to prevent metastasis to different organs of the body including the brain. He is working to develop novel therapies to target cancer in the brain and to prevent resistance to established therapies.
Milan Makale, PhD, MSEE, is a Research Scientist-Bioengineer in Neuro-Oncology at the Moores Cancer Center. He is a member of the Basic Science and Translational Laboratory lead by Dr. Santosh Kesari.
Dr. Harismendy has a decade of experience in functional genomics and has been working in translational genomics for the past six years, developing assays and analysis for targeted sequencing, exploring the role of regulatory variants in common diseases, and improving the detection of somatic mutations in cancer. Most recently, he has been implementing an Ultra Deep Targeted Sequencing assay to detect low-prevalence mutations in clinical samples, with the intent of advancing research to ultimately provide a comprehensive personalized molecular profile of solid tumors.
Stephen Howell,, Professor of Medicine, Associate Director for Research Education and Training
Dr. Howell is a tenured Professor of Medicine with more than 35 years of experience as a principal investigator in basic science, translational research, and both investigator-initiated and industry-initiated clinical research. Over the past decade, he has focused on understanding the cellular pharmacology of platinum drugs, a class of chemotherapy drugs that trigger cell death in cancerous tumors, and the development of additional drug delivery systems for platinum-containing chemotherapeutic agents.
San Diego ABC 10 News reporter Michael Chen interviewed San Diego resident Linda Lowe, a patient of Moores Cancer Center Investigator Dr. Catriona Jamieson, along with Moores Cancer Center Director of Industry Relations Ida Deichaite, PhD , in a video report from the 6PM News on April 11 covering the successful 9th Industry/Academia Translational Oncology Symposium.